# Endocrinology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: George H. W. Bush (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML018-SYN-TD
- Date: 1991-05-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Douglas Whitford, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Anjali Kapoor, MD, Endocrinology
- Urgency: Urgent, within two weeks

## Referral question

New paroxysmal atrial fibrillation in a fit 66-year-old, with thyroid tests showing hyperthyroidism and a positive TSH receptor antibody. Please confirm Graves' disease, assess the eyes, and advise on definitive treatment and on the thyroid course afterwards. **S**

## Questions for the consultant

1. Do you agree this is Graves' disease, or is an uptake scan needed to exclude a nodular goiter or thyroiditis?
2. Which definitive treatment do you advise (radioactive iodine, long-term methimazole, or surgery), given his age and atrial fibrillation?
3. How should methimazole and the beta-blocker be handled before and after treatment?
4. Is there any Graves' orbitopathy, and does he need steroid cover?
5. What thyroid course should we expect afterwards, and when should levothyroxine start?

## Pertinent history

Atrial fibrillation began four days ago as unusual tiredness while running, with a fast ventricular rate on arrival at hospital. ECG showed no abnormality apart from the rhythm, and the echocardiogram was normal. Sinus rhythm returned on medication without cardioversion, with one brief recurrence before discharge. Discharged on metoprolol succinate 50 mg daily and apixaban 5 mg twice daily (CHA2DS2-VASc 1, HAS-BLED 1, shared decision). Today: sinus rhythm at 88; TSH 0.005 mIU/L, free T4 3.6 ng/dL, total T3 280 ng/dL, TSH receptor antibody 8.2 IU/L; white cell count 6.8 and neutrophils 3.9 x10³/µL; ALT 32 U/L; creatinine 0.92 mg/dL. Diffusely enlarged, non-tender thyroid; no eye signs. Never used tobacco. Methimazole 20 mg daily started today. **S**

- George Herbert Walker Bush was born in Milton, Massachusetts, on June 12, 1924. **D**
- On May 4, 1991, he developed atrial fibrillation while running at Camp David; it presented as unusual fatigue during the run. He was flown to Bethesda Naval Hospital, where an electrocardiogram showed no abnormality except the irregular rhythm and a cardiac ultrasound showed no structural abnormality and normal heart function. Treatment began with digoxin. **D**
- On May 5, 1991, the White House said he still had atrial fibrillation, with no sign of heart damage or heart attack, and that procainamide had been added to digoxin; electrical cardioversion would be considered if the rhythm did not return to normal. **D**
- His normal rhythm returned late on May 5, atrial fibrillation recurred early on May 6, and cardioversion was judged unnecessary because his response to medication was encouraging. He was discharged on May 6 and was in normal sinus rhythm later that day, on digoxin and procainamide. **D**
- Later in the same week he was diagnosed with Graves' disease. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: TSH: 0.005 mIU/L (low); Free T4: 3.6 ng/dL (high); Total T3: 280 ng/dL (high); TSH receptor antibody: 8.2 [IU]/L (high); White cell count: 6.8 10*3/uL; Absolute neutrophil count: 3.9 10*3/uL; Hemoglobin: 14.8 g/dL; ALT: 32 U/L; Creatinine: 0.92 mg/dL; eGFR: 87 mL/min/1.73 m²; Potassium: 4.2 mmol/L. All results are synthetic.

BP 142/68 mmHg; pulse 88 bpm; respirations 16/min; temperature 37.1 °C; oxygen saturation 98% on room air; weight 86 kg; BMI 24.3 kg/m². All vital signs are synthetic.

## Current medications

- Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital) **S**
- Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital) **S**
- Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth daily **S**

## Plan so far

- Rate control with metoprolol succinate 50 mg daily; no antiarrhythmic drug or cardioversion while thyrotoxic, because most thyrotoxic atrial fibrillation reverts once thyroid levels are normal; taper the beta-blocker once he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Stroke-risk and bleeding-risk scoring (CHA2DS2-VASc 1 for age 65 to 74; HAS-BLED 1 for age over 65) with a shared decision to continue apixaban 5 mg twice daily while thyrotoxic, then reassess once sustained sinus rhythm is confirmed after he is no longer thyrotoxic. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Methimazole 20 mg daily after a baseline blood count and liver tests, with written advice to stop it and call at once for fever, sore throat, mouth ulcers, jaundice, or dark urine; stop three days before radioactive iodine. Guideline: 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) **S**
- Atrial fibrillation monitoring at every visit (heart rate and rhythm, blood pressure, weight, symptoms, activity, alcohol, tobacco), ECG when indicated, echocardiogram at diagnosis, CHA2DS2-VASc and HAS-BLED yearly, creatinine and blood count at baseline and yearly on apixaban, and sleep apnea screening at diagnosis and yearly. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
- Return to running in steps once the heart rate is controlled, aiming for about 210 minutes a week of moderate to vigorous activity; limit alcohol to no more than one drink a day. Guideline: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026) **S**
